Business Monitor International


Iraq Pharmaceuticals & Healthcare Report

Published 07 April 2014

  • 78 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Iraq Pharmaceuticals & Healthcare Report

BMI View: Thanks to the government's expansionary fiscal policy, spending on education, health and public services will increase . The Iraqi government has reportedly pledged to invest USD12bn into healthcare expansions in 2014, and the Ministry of Health recently awarded 18 health project contracts worth USD276mn . In addition, n ew restrictions aim to end the chaos in which materials have entered the country in previous years , targeting control over drug policy and ensuring the supply of medicines in adequate quantities and at reasonable prices. In general, the projected growth of Iraq's pharmaceutical market in 2014 and 2015 is linked to an oil-driven economic expansion, which is dependent on the government's ability to represent and appease the country's factions. Numerous factors, however, will continue to hamper market growth.

Headline Expenditure Projections

  • Pharmaceuticals: IQD1,573bn (USD1.35bn) in 2013 to IQD1,772bn (USD1.52bn) in 2014; +12.6% in local currency and +12.8% in US dollar terms. Forecast unchanged from Q214. 

  • Healthcare: IQD9,701bn (USD8.33bn) in 2013 to IQD10,477bn (USD9.01bn) in 2014; +8.0% in local currency and +8.2% in US dollar terms. Forecast substantially lowered from Q214 due to macroeconomic conditions.

Risk/Reward Rating

Iraq's Pharmaceutical Risk/Reward Rating (RRR) score for Q314 reflects the market's potential and its strong economic growth prospects. It performs better in terms of Rewards than Risks. In Q314 Iraq scores 41.9 out of 100, making it the 16th most attractive pharmaceutical market in the Middle East and African region. While its score has increased, the country's position is unchanged from Q214.

Key Trends And Developments

In May 2014, Zawya reported that Brazil exported pharmaceutical products worth USD15.5mn to Arab countries in 2013, citing the Arab-Brazilian Chamber of Commerce (ABCC). The top five importers were Egypt, Saudi Arabia, Sudan, Iraq and the United Arab Emirates. Brazil's...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales Indicators 2009-2017
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Indicators 2009-2017
18
Table: Healthcare Governmental Indicators 2009-2017
19
Table: Healthcare Private Indicators 2009-2017
19
Economic Analysis
20
Private Consumption Outlook
21
Fixed Investment Outlook
22
Government Spending Outlook
23
Net Exports
24
Risks To Outlook
25
Table: Iraq - Economic Activity
25
Pharmaceutical Trade Forecast
26
Table: Exports And Imports Indicators, 2009-2017
27
Other Healthcare Data
28
Key Risks To BMI's Forecast Scenario
30
Industry Risk Reward Ratings
31
Industry Risk/Reward Ratings
31
Table: Pharmaceuticals & Healthcare Q213 Risk/Reward Ratings
31
Rewards
32
Risks
33
Market Overview
34
Industry Trends And Developments
35
Epidemiology
35
Healthcare Sector
38
Healthcare Infrastructure
43
Clinical Trials
44
Regulatory Development
45
Regulatory Regime
45
Intellectual Property Issues
47
Pricing Regime
49
Reimbursement Regime
50
Competitive Landscape
51
Pharmaceutical Sector
51
Pharmaceutical Company Developments
53
Pharmaceutical Distribution
53
Pharmaceutical Retail Sector
53
Company Profile
55
Samarra
55
Ninewa
57
GlaxoSmithKline
59
Demographic Forecast
61
Table: Iraq's Population By Age Group, 1990-2020 ('000)
62
Table: Iraq's Population By Age Group, 1990-2020 (% of total)
62
Table: Iraq's Key Population Ratios, 1990-2020
63
Table: Iraq's Rural And Urban Population, 1990-2020
63
Glossary
64
Methodology
66
Methodology
66
Risk/Reward Ratings Methodology
66
Ratings Overview
67
Table: Pharmaceutical Business Environment Indicators
67
Weighting
68
Table: Weighting Of Components
68
Sources
68

The Iraq Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Iraq Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Iraqi pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Iraq to test other views - a key input for successful budgeting and strategic business planning in the Iraqi pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Iraqi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Iraq.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc